Retinal vein thrombosis: Pathogenesis and management

Journal of Thrombosis and Haemostasis

Volumn 8, Issue 9, 2010, Pages 1886-1894

  Rehak, M ^a   Wiedemann, P ^a  

^a UNIVERSITY OF LEIPZIG   (Germany)

Author keywords

Pathogenesis; Prognosis; Retinal vein occlusion; Treatment

Indexed keywords

ACETYLSALICYLIC ACID; ALTEPLASE; BEVACIZUMAB; DEXAMETHASONE; DEXTRAN; DIURETIC AGENT; HEPARIN; HETASTARCH; ORAL CONTRACEPTIVE AGENT; PEGAPTANIB; RANIBIZUMAB; STEROID; TICLOPIDINE; TRIAMCINOLONE ACETONIDE; TROXERUTIN;

ANTIPHOSPHOLIPID SYNDROME; ANTITHROMBIN DEFICIENCY; BLOOD VESSEL WALL; BLURRED VISION; BODY MASS; BRANCH RETINAL VEIN OCCLUSION; CATARACT; CENTRAL RETINA VEIN OCCLUSION; CLINICAL TRIAL; DIABETES MELLITUS; DRUG DOSE COMPARISON; DYSLIPIDEMIA; ERYTHROCYTE AGGREGATION; HEMODILUTION; HUMAN; HYPERHOMOCYSTEINEMIA; HYPERTENSION; INCIDENCE; INTRAOCULAR PRESSURE; IRIS RUBEOSIS; LASER COAGULATION; LEUKEMIA; MULTIPLE MYELOMA; NEOVASCULAR GLAUCOMA; OPTICAL COHERENCE TOMOGRAPHY; POLYCYTHEMIA VERA; PRIORITY JOURNAL; PROTEIN C DEFICIENCY; PROTEIN S DEFICIENCY; RADIAL OPTIC NEUROTOMY; RETINA DETACHMENT; RETINA FLUORESCEIN ANGIOGRAPHY; RETINA MACULA EDEMA; RETINA NEOVASCULARIZATION; RETINA VEIN OCCLUSION; REVIEW; RISK FACTOR; SARCOIDOSIS; SIDE EFFECT; SMOKING; SYPHILIS; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOPHILIA; UNSPECIFIED SIDE EFFECT; VISUAL IMPAIRMENT; VITRECTOMY; VITREOUS HEMORRHAGE;

ALGORITHMS; CLINICAL TRIALS AS TOPIC; HUMANS; LASER COAGULATION; LIGHT; MACULAR EDEMA; OPHTHALMOLOGIC SURGICAL PROCEDURES; PROGNOSIS; RETINAL VEIN; RETINAL VEIN OCCLUSION; RISK FACTORS; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VENOUS THROMBOSIS; VISION, OCULAR;

EID: 77956470220     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2010.03909.x     Document Type: Review

References (79)

1. Hayreh SS, Zimmerman B, Podhajsky P. Incidence of various types of retinal vein occlusion and their recurrence and demographic characteristics. Am J Ophthalmol 1990, 117:429-41.
2. Ip MS, Oden NL, Scott IU, VanVeldhuisen PC, Blodi BA, Figueroa M, Antoszyk A, Elman M. SCORE Study report 3: study design and baseline characteristics. Ophthalmology 2009, 116:1770-7.
3. Hayreh SS. Prevalent misconceptions about acute retinal vascular occlusive disorders. Prog Retin Eye Res 2005, 24:493-519.
4. Feman SS, Stein RS. Waldenstrom's macroglobulinemia, a hyperviscosity manifestation of venous stasis retinopathy. Int Ophthalmol 1981, 4:107-12.
5. Brunette I, Boghen D. Central retinal vein occlusion complicating spontaneous carotid-cavernous fistula. Case report. Arch Ophthalmol 1987, 105:464-5.
6. Duker JS, Sergott RC, Savino PJ, Bosley TM. Optic neuritis with secondary retinal venous stasis. Ophthalmology 1989, 96:475-80.
7. Rogers S, McIntosh RL, Cheung N, Lim L, Wang JJ, Mitchell P, Kowalski JW, Nguyen H, Wong TY. The prevalence of retinal vein occlusion: pooled data from population studies from the United States, Europe, Asia, and Australia. Ophthalmology 2010, 117:313-9.
8. Yau JW, Lee P, Wong TY, Best J, Jenkins A. Retinal vein occlusion: an approach to diagnosis, systemic risk factors and management. Intern Med J 2008, 38:904-10.
9. David R, Zangwill L, Badarna M, Yassur Y. Epidemiology of retinal vein occlusion and its association with glaucoma and increased intraocular pressure. Ophthalmologica 1988, 197:69-74.
10. Appiah AP, Trempe CL. Differences in contributory factors among hemicentral, central, and branch retinal vein occlusions. Ophthalmology 1989, 96:364-6.
11. Wong TY, Larsen EK, Klein R, Mitchell P, Couper DJ, Klein BE, Hubbard LD, Siscovick DS, Sharrett AR. Cardiovascular risk factors for retinal vein occlusion and arteriolar emboli: the Atherosclerosis Risk in Communities & Cardiovascular Health studies. Ophthalmology 2005, 112:540-7.
12. Rath EZ, Frank RN, Shin DH, Kim C. Risk factors for retinal vein occlusions. A case-control study. Ophthalmology 1992, 99:509-14.
13. Risk factors for central retinal vein occlusion. The Eye Disease Case-Control Study Group. Arch Ophthalmol 1996, 114:545-54.
14. Risk factors for branch retinal vein occlusion. The Eye Disease Case-Control Study Group. Am J Ophthalmol 1993, 116:286-96.
15. Hayreh SS, Zimmerman B, McCarthy MJ, Podhajsky P. Systemic diseases associated with various types of retinal vein occlusion. Am J Ophthalmol 2001, 131:61-77.
16. Cheung N, Klein R, Wang JJ, Cotch MF, Islam AF, Klein BE, Cushman M, Wong TY. Traditional and novel cardiovascular risk factors for retinal vein occlusion: the multiethnic study of atherosclerosis. Invest Ophthalmol Vis Sci 2008, 49:4297-302.
17. Fong AC, Schatz H. Central retinal vein occlusion in young adults. Surv Ophthalmol 1993, 37:393-417.
18. Kuhli-Hattenbach C, Scharrer I, Lüchtenberg M, Hattenbach LO. Selective thrombophilia screening of young patients with retinal vein occlusion. Klin Monatsbl Augenheilkd 2009, 226:768-73.
19. Rehak M, Rehak J, Müller M, Faude S, Faude F, Siegemund A, Krcova V, Slavik L, Hasenclever D, Scholz M, Wiedemann P. The prevalence of activated protein C (APC) resistance and factor V Leiden is significantly higher in patients with retinal vein occlusion without general risk factors. Case-control study and meta-analysis. Thromb Haemost 2008, 99:925-9.
20. O'Mahoney PR, Wong DT, Ray JG. Retinal vein occlusion and traditional risk factors for atherosclerosis. Arch Ophthalmol 2008, 126:692-9.
21. Jefferies P, Clemett R, Day T. An anatomical study of retinal arteriovenous crossings and their role in the pathogenesis of retinal branch vein occlusions. Aust N Z J Ophthalmol 1993, 21:213-7.
22. Seitz R. The Retinal Vessels: Comparative Ophthalmoscopic and Histologic Studies on Healthy and Diseased Eyes 1964, St. Louis, MO, CV Mosby
23. Frangieh GT, Green WR, Barraquer-Somers E, Finkelstein D. Histopathologic study of branch retinal vein occlusion. Arch Ophthalmol 1982, 100:1132-40.
24. Zhao J, Sastry SM, Sperduto RD, Chew EY, Remaley NA. Arteriovenous crossing patterns in branch retinal vein occlusion. Ophthalmology 1993, 100:423-8.
25. Christoffersen NL, Larsen M. Pathophysiology and hemodynamic of branch retinal vein occlusion. Ophthalmology 1999, 106:2054-62.
26. McGrath MA, Wechsler F, Hunyor AB, Penny R. Systemic factors contributory to retinal vein occlusion. Arch Intern Med 1978, 138:216-20.
27. Janssen MC, den Heijer M, Cruysberg JR, Wollersheim H, Bredie SJ. Retinal vein occlusion: a form of venous thrombosis or a complication of atherosclerosis? A meta-analysis of thrombophilic factors. Thromb Haemost 2005, 93:1021-6.
28. Cahill MT, Stinnett SS, Fekrat S. Meta-analysis of plasma homocysteine, serum folate, serum vitamin B(12), and thermolabile MTHFR genotype as risk factors for retinal vascular occlusive disease. Am J Ophthalmol 2003, 136:1136-50.
29. McGimpsey SJ, Woodside JV, Cardwell C, Cahill M, Chakravarthy U. Homocysteine, methylenetetrahydrofolate reductase C677T polymorphism, and risk of retinal vein occlusion: a meta-analysis. Ophthalmology 2009, 116:1778-87.
30. Rehak M, Müller M, Scholz M, Wiercinska J, Niederwieser D, Wiedemann P. Antiphospholipid syndrome and retinal vein occlusion. Meta-analysis of Published Studies. Ophthalmologe 2009, 106:427-34.
31. Welch GN, Loscalzo J. Homocysteine and atherothrombosis. N Engl J Med 1998, 338:1142-50.
32. Arsene S, Delahousse B, Regina S, Le Lez ML, Pisella PJ, Gruel Y. Increased prevalence of factor V Leiden in patients with retinal vein occlusion and under 60 years of age. Thromb Haemost 2005, 94:101-6.
33. Linna T, Ylikorkala A, Kontula K, Puska P, Tervo T. Prevalence of factor V Leiden in young adults with retinal vein occlusion. Thromb Haemost 1997, 77:214-6.
34. Kuhli C, Hattenbach LO, Scharrer I, Koch F, Ohrloff C. High prevalence of resistance to APC in young patients with retinal vein occlusion. Graefes Arch Clin Exp Ophthalmol 2002, 240:163-8.
35. Cruciani F, Moramarco A, Curto T, Labate A, Recupero V, Conti L, Gandolfo GM, Balacco Gabrieli C. MTHFR C677T mutation, factor II G20210A mutation and factor V Leiden as risks factor for youth retinal vein occlusion. Clin Ter 2003, 154:299-303.
36. Gottlieb JL, Blice JP, Mestichelli B, Konkle BA, Benson WE. Activated protein C resistance, factor V Leiden, and central retinal vein occlusion in young adults. Arch Ophthalmol 1998, 116:577-9.
37. Rehak M, Krcova V, Slavik L, Fric E, Langova K, Ulehova J, Rehak J. The role of thrombophilia in patients with retinal vein occlusion without systemic risk factors. Can J Ophthalmol 2010, 45:171-5.
38. Pengo V, Ruffatti A, Legnani C, Gresele P, Barcellona D, Erba N, Testa S, Marongiu F, Bison E, Denas G, Banzato A, Padayattil Jose S, Iliceto S. Clinical course of high risk patients diagnosed with Antiphospholipid Syndrome (APS). J Thromb Haemost 2010, 8:234-6.
39. Tripodi A. Testing for lupus anticoagulants: all that a clinician should know. Lupus 2009, 18:291-8.
40. Squizzato A, Manfredi E, Bozzato S, Dentali F, Ageno W. Antithrombotic and fibrinolytic drugs for retinal vein occlusion: a systematic review and a call for action. Thromb Haemost 2010, 103:271-6.
41. Baseline and early natural history report. The Central Vein Occlusion Study. Arch Ophthalmol 1993, 111:1087-95.
42. Lang GE, Freissler K. Clinical and fluorescein angiography findings in patients with retinal vein occlusion. A unicenter study of 211 patients. Klin Monatsbl Augenheilkd 1992, 201:234-9.
43. Kuo HK, Kuo MT, Chen YJ, Wu PC, Chen CH, Chen YH. The flicker electroretinogram interocular amplitude ratio is a strong prognostic indicator of neovascularization in patients with central retinal vein occlusion. Graefes Arch Clin Exp Ophthalmol 2010, 248:185-9.
44. Michels RG, Gass JDM. Natural course of temporal retinal branch occlusion. Trans Am Acad Ophthalmol Otolaryngol 1974, 78:166-77.
45. Shilling JS, Jones CA. Retinal branch vein occlusion: a study of argon laser photocoagulation in the treatment of macular oedema. Br J Ophthalmol 1984, 68:196-8.
46. Rehak J, Rehak M. Branch retinal vein occlsuion: pathogenesis, visual prognosis, and treatment modalities. Curr Eye Res 2008, 33:111-31.
47. Argon laser scatter photocoagulation for prevention of neovascularization and vitreous hemorrhage in branch vein occlusion: a randomized clinical trial. Branch Vein Occlusion Study Group. Arch Ophthalmol 1986, 104:34-41.
48. Ota M, Tsujikawa A, Murakami T, Kita M, Miyamoto K, Sakamoto A, Yamaike N, Yoshimura N. Association between integrity of foveal photoreceptor layer and visual acuity in branch retinal vein occlusion. Br J Ophthalmol 2007, 91:1644-9.
49. Glacet-Bernard A, Coscas G, Chabanel A, Zourdani A, Lelong F, Samama MM. Prognostic factors for retinal vein occlusion: prospective study of 175 cases. Ophthalmology 1996, 103:551-60.
50. Quinlan PM, Elman MJ, Bhatt AK, Mardesich P, Enger C. The natural course of central retinal vein occlusion. Am J Ophthalmol 1990, 110:118-23.
51. Chaine G, Tolub O, Français C, Coscas G. Unfavorable prognostic elements in occlusions of the central retinal vein of the edematous type. Bull Mem Soc Fr Ophtalmol 1985, 96:403-6.
52. Natural history and clinical management of central retinal vein occlusion. The Central Vein Occlusion Study Group. Arch Ophthalmol 1997, 115:486-91.
53. McIntosh RL, Mohamed Q, Saw SM, Wong TY. Interventions for branch retinal vein occlusion: an evidence-based systematic review. Ophthalmology 2007, 114:835-54.
54. Mohamed Q, McIntosh RL, Saw SM, Wong TY. Interventions for central retinal vein occlusion: an evidence-based systematic review. Ophthalmology 2007, 114:507-24.
55. Weiss JN, Bynoe LA. Injection of tissue plasminogen activator into a branch retinal vein in eyes with central retinal vein occlusion. Ophthalmology 2001, 108:2249-57.
56. Höh AE, Schaal KB, Dithmar S. Central and branch retinal vein occlusion. Current strategies for treatment in Germany, Austria and Switzerland. Ophthalmologe 2007, 104:290-4.
57. Hattenbach LO, Friedrich Arndt C, Lerche R, Scharrer I, Baatz H, Margaron F, Richard G, Behrens-Baumann W, Ohrloff C. Retinal vein occlusion and low-dose fibrinolytic therapy (R.O.L.F.): a prospective, randomized, controlled multicenter study of low-dose recombinant tissue plasminogen activator versus hemodilution in retinal vein occlusion. Retina 2009, 29:932-40.
58. Houtsmuller AJ, Vermeulen JA, Klompe M, Zahn KJ, Henkes HE, Baarsma GS, Tijssen J. The influence of ticlopidine on the natural course of retinal vein occlusion. Agents Actions Suppl 1984, 15:219-29.
59. Glacet-Bernard A, Coscas G, Chabanel A, Zourdani A, Lelong F, Samama MM. A randomized, double-masked study on the treatment of retinal vein occlusion with troxerutin. Am J Ophthalmol 1994, 118:421-9.
60. A randomized clinical trial of early panretinal photocoagulation for ischemic central vein occlusion: the Central Vein Occlusion Study Group. Ophthalmology 1995, 102:1434-44.
61. Evaluation of grid pattern photocoagulation for macular edema in central vein occlusion: the Central Vein Occlusion Study Group. Ophthalmology 1995, 102:1425-33.
62. Yamamoto S, Saito W, Yagi F, Takeuchi S, Sato E, Mizunoya S. Vitrectomy with or without arteriovenous adventitial sheathotomy for macular edema associated with branch retinal vein occlusion. Am J Ophthalmol 2004, 138:907-14.
63. Charbonnel J, Glacet-Bernard A, Korobelnik J, Nyouma-Moune E, Pournaras CJ, Colin J, Coscas G, Soubrane G. Management of branch retinal vein occlusion with vitrectomy and arteriovenous adventitial sheathotomy: the possible role of surgical posterior vitreous detachment. Graefes Arch Clin Exp Ophthalmol 2004, 242:223-8.
64. Tachi N, Hashimoto Y, Ogino N. Vitrectomy for macular oedema combined with retinal vein occlusion. Doc Ophthalmol 1999, 97:465-9.
65. Rehak M, Hollborn M, Iandiev I, Pannicke T, Karl A, Wurm A, Kohen L, Reichenbach A, Wiedemann P, Bringmann A. Retinal gene expression and Müller cell responses after branch retinal vein occlusion in the rat. Invest Ophthalmol Vis Sci 2009, 50:2359-67.
66. Adamis AP, Shima DT. The role of vascular endothelial growth factor in ocular health and disease. Retina 2005, 25:111-8.
67. Bringmann A, Reichenbach A, Wiedemann P. Pathomechanisms of cystoid macular edema. Ophthalmic Res 2004, 36:241-9.
68. Sivaprasad S, McCluskey P, Lightman S. Intravitreal steroids in the management of macular edema. Acta Ophthalmol Scand 2006, 84:722-33.
69. Chen SD, Sundaram V, Lochhead J, Patel CK. Intravitreal triamcinolone for the treatment of ischemic macular edema associated with branch retinal vein occlusion. Am J Ophthalmol 2006, 141:876-83.
70. Krepler K, Ergun E, Sacu S, Richter-Muksch S, Wagner J, Stur M, Wedrich A. Intravitreal triamcinolone acetonide in patients with macular oedema due to branch retinal vein occlusion: a pilot study. Acta Ophthalmol Scand 2005, 83:600-4.
71. Wakabayashi T, Okada AA, Morimura Y, Kojima E, Asano Y, Hirakata A, Hida T. Trans-tenon retrobulbar triamcinolone infusion for chronic macular edema in central and branch retinal vein occlusion. Retina 2004, 24:964-7.
72. Scott IU, Ip MS, VanVeldhuisen PC, Oden NL, Blodi BA, Fisher M, Chan CK, Gonzalez VH, Singerman LJ, Tolentino M. A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with standard care to treat vision loss associated with macular Edema secondary to branch retinal vein occlusion: the Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) study report 6. Arch Ophthalmol 2009, 127:1115-28.
73. Kuppermann BD, Blumenkranz MS, Haller JA, Williams GA, Weinberg DV, Chou C, Whitcup SM. Randomized controlled study of an intravitreous dexamethasone drug delivery system in patients with persistent macular edema. Arch Ophthalmol 2007, 125:09-17.
74. Wu L, Arevalo JF, Berrocal MH, Maia M, Roca JA, Morales-Cantón V, Alezzandrini AA, Díaz-Llopis MJ. Comparison of two doses of intravitreal bevacizumab as primary treatment for macular edema secondary to branch retinal vein occlusions: results of the Pan American Collaborative Retina Study Group at 24 Months. Retina 2009, 29:1396-403.
75. Cheng KC, Wu WC, Chen KJ. Intravitreal triamcinolone acetonide vs bevacizumab for treatment of macular oedema secondary to branch retinal vein occlusion. Eye 2009, 23:2023-33.
76. Rouvas A, Petrou P, Vergados I, Pechtasides D, Liarakos V, Mitsopoulou M, Ladas I. Intravitreal ranibizumab (Lucentis) for treatment of central retinal vein occlusion: a prospective study. Graefes Arch Clin Exp Ophthalmol 2009, 247:1609-16.
77. Spaide RF, Chang LK, Klancnik JM, Yannuzzi LA, Sorenson J, Slakter JS, Freund KB, Klein R. Prospective study of intravitreal ranibizumab as a treatment for decreased visual acuity secondary to central retinal vein occlusion. Am J Ophthalmol 2009, 147:298-306.
78. Pieramici DJ, Rabena M, Castellarin AA, Nasir M, See R, Norton T, Sanchez A, Risard S, Avery RL. Ranibizumab for the treatment of macular edema associated with perfused central retinal vein occlusions. Ophthalmology 2008, 115:47-54.
79. Grisanti S, Biester S, Peters S, Tatar O, Ziemssen F, Bartz-Schmidt KU. Intracameral bevacizumab for iris rubeosis. Am J Ophthalmol 2006, 142:158-60.